Investor Presentaiton

H1 FY23 SUMMARY RESULTS EBOS achieved another record half year result, driven by organic growth and contribution from acquisitions $m Revenue EBITDA EBIT NPAT EPS (cents) DPS (NZ cents) EBITDA margin ROCE (%) Net debt EBITDA (x) Underlying¹ 6,145.7 289.2 239.5 141.6 74.5 4.71% 14.4% 1.76x Var Statutory 17.0% 6,145.7 Var² 17.0% 39.3% 289.2 44.7% 41.6% 226.0 ^ 40.1% 29.6% 132.2 Δ 29.8% 12.0% 69.6 13.3% 53.0 12.8% ববববব বচ 76bp (3.8%) 0.18x2 Substantial Strong organic earnings growth contribution from FY22 acquisitions Double-digit EPS growth Gearing reduced and within target range Increased dividends to shareholders 13 Notes: 1. Underlying earnings for the 31 December 2022 period exclude the amortisation (non-cash) expense attributable to the LifeHealthcare acquisition purchase price accounting (PPA) of finite life intangible assets ($13.5m pre tax, $9.4m post tax). Underlying earnings for the 31 December 2021 period exclude transaction costs incurred on M&A ($7.8m pre tax, $7.4m post tax). 2. Comparisons shown to prior corresponding period with exception of Net Debt: EBITDA, which is compared to June 2022. ROCE in-line with expectations after LifeHealthcare acquisition EBOS GROUP LIMITED

View entire presentation